IL-6, as a key upstream regulator of JAK/STAT signaling, can activate STAT3 and related downstream molecules, enhance thrombopoietin expression, and drive excessive myeloid proliferation, ultimately leading to secondary (reactive) thrombocytosis (14). The gene discussed is STAT3; the disease is thrombocytosis disease.